Clinical trial · Interventional
Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)
Open-label, Randomised, Phase 2 Study in Patients With Advanced Solid Tumours to Determine Effect of Food Upon Pharmacokinetics of a Single Oral Dose of Cediranib (AZD2171, Recentin™), Followed by an Assessment of the Safety & Tolerability of Fixed and Individualised Daily Dosing
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether food has any effect on a single dose of Cediranib (AZD2171, Recentin™)followed by an assessment of the safety and tolerability of fixed daily dosing in comparison to varying dose levels on a patient-by-patient basis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Cediranib 45 mg Fed
- description
- Part A: Cediranib 45 mg Fed State
- interventionNames
- Drug: Cediranib
- type
- EXPERIMENTAL
- label
- Cediranib 45 mg Fasted
- description
- Part A: Cediranib 45 mg Fasted State
- interventionNames
- Drug: Cediranib
- type
- EXPERIMENTAL
- label
- Cediranib 45 mg Fixed Dose
- description
- Part B: Cediranib 45 mg Fixed Dose
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of advanced solid tumour. * Ability to eat a high fat breakfast Exclusion Criteria: * Poorly controlled high blood pressure. * History of significant gastrointestinal problems
References
Publications (0)
Data not yet available